PTC Therapeutics Beats Guidance with $263M Q4 Revenue, $92M Sephience Sales
PTC Therapeutics reported Q4 net product and royalty revenue of $263 million and full-year 2025 revenue of $831 million, exceeding its $750–800 million guidance. Sephience generated $92 million in Q4 sales ($81 million U.S.) and company guides 2026 product revenue to $700–800 million with potential cash-flow breakeven.
1. Q4 and Full-Year 2025 Financial Results
PTC Therapeutics delivered Q4 net product and royalty revenue of $263 million and full-year 2025 total net product and royalty revenue of $831 million, surpassing the prior guidance range of $750–800 million. Full-year performance benefited from another strong quarter in both its core and new product lines.
2. Sephience Launch and Commercial Performance
Sephience, launched in 2025, generated $92 million in Q4 sales, with $81 million in the U.S. and $11 million ex-U.S., serving 946 patients by year end. Uptake spanned all age groups and severities, with early refill rates strong and patient discontinuations in the single digits.
3. Cash Position and 2026 Guidance
PTC ended 2025 with $1.95 billion in cash following a $240 million upfront payment from a royalty sale and guided product revenue of $700–800 million for 2026. Management anticipates reaching cash-flow breakeven during the year based on continued Sephience momentum and controlled operating expenses.
4. Pipeline and International Expansion
The company plans to broaden Sephience’s footprint to 20–30 countries by end-2026, with Germany, Japan and Brazil programs advancing through pricing and reimbursement stages. In development, Novartis will initiate the phase III INVEST-HD trial of Votoplam in H1 2026 while additional studies are expected for Vatiquinone before NDA resubmission.